Anti-cancer Pro-inflammatory Effects of an IgE Antibody Targeting the Melanoma-associated Antigen Chondroitin Sulfate Proteoglycan 4

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
25 Downloads (Pure)

Abstract

Outcomes for half of patients with melanoma remain poor despite standard-of-care checkpoint inhibitor therapies. The prevalence of the melanoma-associated antigen chondroitin sulfate proteoglycan 4 (CSPG4) expression is ~70%, therefore effective immunotherapies directed at CSPG4 could benefit many patients. Since IgE exerts potent immune-activating functions in tissues, we engineer a monoclonal IgE antibody with human constant domains recognizing CSPG4 to target melanoma. CSPG4 IgE binds to human melanomas including metastases, mediates tumoricidal antibody-dependent cellular cytotoxicity and stimulates human IgE Fc-receptor-expressing monocytes towards pro-inflammatory phenotypes. IgE demonstrates anti-tumor activity in human melanoma xenograft models engrafted with human effector cells and is associated with enhanced macrophage infiltration, enriched monocyte and macrophage gene signatures and pro-inflammatory signaling pathways in the tumor microenvironment. IgE prolongs the survival of patient-derived xenograft-bearing mice reconstituted with autologous immune cells. No ex vivo activation of basophils in patient blood is measured in the presence of CSPG4 IgE. Our findings support a promising IgE-based immunotherapy for melanoma.

Original languageEnglish
Article number2192
JournalNature Communications
Volume14
Issue number1
DOIs
Publication statusPublished - 25 Apr 2023

Fingerprint

Dive into the research topics of 'Anti-cancer Pro-inflammatory Effects of an IgE Antibody Targeting the Melanoma-associated Antigen Chondroitin Sulfate Proteoglycan 4'. Together they form a unique fingerprint.

Cite this